Participation of pro- and anti-nociceptive interleukins in botulinum toxin A-induced analgesia in a rat model of neuropathic pain

European Journal of Pharmacology

Volumn 791, Issue , 2016, Pages 377-388

  Zychowska, Magdalena ^a   Rojewska, Ewelina ^a   Makuch, Wioletta ^a   Luvisetto, Siro ^b   Pavone, Flaminia ^b   Marinelli, Sara ^b   Przewlocka, Barbara ^a   Mika, Joanna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Botulinum neurotoxin A; Glia; Interleukins; Minocycline; Neuropathic pain model

Indexed keywords

BOTULINUM TOXIN A; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MINOCYCLINE; ANALGESIC AGENT; BIOLOGICAL MARKER; INTERLEUKIN DERIVATIVE;

ANALGESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG POTENTIATION; GLIA CELL; LUMBAR SPINAL CORD; MALE; MICROGLIA; MOTOR PERFORMANCE; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; SCIATIC NERVE INJURY; SPINAL CORD; SPINAL GANGLION; UPREGULATION; WESTERN BLOTTING; ANIMAL; ASTROCYTE; DRUG EFFECTS; EXPLORATORY BEHAVIOR; METABOLISM; MOTOR ACTIVITY; NEURALGIA; PATHOPHYSIOLOGY; TIME FACTOR; WISTAR RAT;

ANALGESICS; ANIMALS; ASTROCYTES; BEHAVIOR, ANIMAL; BIOMARKERS; BOTULINUM TOXINS, TYPE A; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; EXPLORATORY BEHAVIOR; GANGLIA, SPINAL; INTERLEUKINS; MALE; MICROGLIA; MINOCYCLINE; MOTOR ACTIVITY; NEURALGIA; NOCICEPTION; RATS; RATS, WISTAR; TIME FACTORS;

EID: 84987918398     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2016.09.019     Document Type: Article

References (75)

1. Antonucci, F., Rossi, C., Gianfranceschi, L., Rossetto, O., Caleo, M., Long-distance retrograde effects of botulinum neurotoxin A. J. Neurosci. 28 (2008), 3689–3696.
2. Austin, P.J., Moalem-Taylor, G., The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. J. Neuroimmunol. 229 (2010), 26–50.
3. Bach-Rojecky, L., Relja, M., Lackovic, Z., Botulinum toxin type A in experimental neuropathic pain. J. Neural Transm. 112 (2005), 215–219.
4. Bach-Rojecky, L., Lacković, Z., Central origin of the antinociceptive action of botulinum toxin type A. Pharmacol. Biochem. Behav. 94 (2009), 234–238.
5. Bennett, G.J., Xie, Y.K., A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33 (1988), 87–107.
6. Brundula, V., Rewcastle, N.B., Metz, L.M., Bernard, C.C., Yong, V.W., Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125 (2002), 1297–1308.
7. Chen, S., Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins 4 (2012), 913–939.
8. Cui, M., Khanijou, S., Rubino, J., Aoki, K.R., Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107 (2004), 125–133.
9. DeLeo, J.A., Tawfik, V.L., LaCroix-Fralish, M.L., The tetrapartite synapse: path to CNS sensitization and chronic pain. Pain 122 (2006), 17–21.
10. Du, Y., Ma, Z., Lin, S., Dodel, R.C., Gao, F., Bales, K.R., Triarhou, L.C., Chernet, E., Perry, K.W., Nelson, D.L., Luecke, S., Phebus, L.A., Bymaster, F.P., Paul, S.M., Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 98 (2001), 14669–14674.
11. Favre-Guilmard, C., Auguet, M., Chabrier, P.E., Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models. Eur. J. Pharmacol. 617 (2009), 48–53.
12. Filipović, B., Matak, I., Bach-Rojecky, L., Lacković, Z., Central action of peripherally applied botulinum toxin type A on pain and dural protein extravasation in rat model of trigeminal neuropathy. PLoS One, 7, 2012, e29803.
13. Foster, K.A., Bigalke, H., Aoki, K.R., Botulinum neurotoxin – from laboratory to bedside. Neurotox. Res. 9 (2006), 133–140.
14. Gazerani, P., Pedersen, N.S., Staahl, C., Drewes, A.M., Arendt-Nielsen, L., Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 141 (2009), 60–69.
15. Habermann, E., 125I-labeled neurotoxin from Clostridium botulinum A: preparation, binding to synaptosomes and ascent to the spinal cord. Naunyn Schmiedebergs Arch. Pharmacol. 281 (1974), 47–56.
16. Hanisch, U.K., Kettenmann, H., Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 10 (2007), 1387–1394.
17. Hargreaves, K., Dubner, R., Brown, F., Flores, C., Joris, J., A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32 (1988), 77–88.
18. Hedrich, C.M., Bream, J.H., Cell type-specific regulation of IL-10 expression in inflammation and disease. Immunol. Res. 47 (2010), 185–206.
19. Hopkins, S.J., Rothwell, N.J., Cytokines and the nervous system. I: expression and recognition. Trends Neurosci. 18 (1995), 83–88 (Review).
20. Johnson, E.A., Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. Annu. Rev. Microbiol. 53 (1999), 551–575.
21. Kielian, T., Esen, N., Liu, S., Phulwani, N.K., Syed, M.M., Phillips, N., Nishina, K., Cheung, A.L., Schwartzman, J.D., Ruhe, J.J., Minocycline modulates neuroinflammation independently of its antimicrobial activity in Staphylococcus aureus-induced brain abscess. Am. J. Pathol. 171 (2007), 1199–1214.
22. Kim, H.S., Suh, Y.H., Minocycline and neurodegenerative diseases. Behav. Brain Res. 196 (2009), 168–179.
23. Kim, S.H., Eisenstein, M., Reznikov, L., Fantuzzi, G., Novick, D., Rubinstein, M., Dinarello, C.A., Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc. Natl. Acad. Sci. USA 97 (2000), 1190–1195.
24. Kim, J.E., Shin, M.S., Seo, T.B., Ji, E.S., Baek, S.S., Lee, S.J., Park, J.K., Kim, C.J., Treadmill exercise ameliorates motor disturbance through inhibition of apoptosis in the cerebellum of valproic acid-induced autistic rat pups. Mol. Med Rep. 8 (2013), 327–334.
25. Kitamura, Y., Matsuka, Y., Spigelman, I., Ishihara, Y., Yamamoto, Y., Sonoyama, W., Kamioka, H., Yamashiro, T., Kuboki, T., Oguma, K., Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction. Neuroscience 159 (2009), 1422–1429.
26. Lam, T.I., Bingham, D., Chang, T.J., Lee, C.C., Shi, J., Wang, D., Massa, S., Swanson, R.A., Liu, J., Beneficial effects of minocycline and botulinum toxin-induced constraintphysical therapy following experimental traumatic brain injury. Neurorehabil. Neural Repair 27 (2013), 889–899.
27. Ledeboer, A., Gamanos, M., Lai, W., Martin, D., Maier, S.F., Watkins, L.R., Quan, N., Involvement of spinal cord nuclear factor kappaB activation in rat models of proinflammatory cytokine-mediated pain facilitation. Eur. J. Neurosci. 22 (2005), 1977–1986.
28. Ledeboer, A., Sloane, E.M., Milligan, E.D., Frank, M.G., Mahony, J.H., Maier, S.F., Watkins, L.R., Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain 115 (2005), 71–83.
29. Ledeboer, A., Jekich, B.M., Sloane, E.M., Mahoney, J.H., Langer, S.J., Milligan, E.D., Martin, D., Maier, S.F., Johnson, K.W., Leinwand, L.A., Chavez, R.A., Watkins, L.R., Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav. Immun. 21 (2007), 686–698.
30. Luvisetto, S., Marinelli, S., Lucchetti, F., Marchi, F., Cobianchi, S., Rossetto, O., Montecucco, C., Botulinum neurotoxins and formalin-induced pain: central vs. peripheral effects in mice. Brain Res. 1082 (2006), 124–131.
31. Luvisetto, S., Gazerani, P., Cianchetti, C., Pavone, F., Botulinum toxin type a as a therapeutic agent against headache and related disorders. Toxins 7 (2015), 3818–3844.
32. Mangione, A.S., Obara, I., Maiarú, M., Geranton, S.M., Tassorelli, C., Ferrari, E., Leese, C., Davletov, B., Hunt, S.P., Nonparalytic botulinum molecules for the control of pain. Pain 157 (2016), 1045–1055.
33. Makuch, W., Mika, J., Rojewska, E., Zychowska, M., Przewlocka, B., Effects of selective and non-selective inhibitors of nitric oxide synthase on morphine and endomorphin-1-induced analgesia in acute and neuropathic pain in rats. Neuropharmacology 75 (2013), 445–457.
34. Marinelli, S., Luvisetto, S., Cobianchi, S., Makuch, W., Obara, I., Mezzaroma, E., Caruso, M., Straface, E., Przewlocka, B., Pavone, F., Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models. Neuroscience 171 (2010), 316–328.
35. Marinelli, S., Vacca, V., Ricordy, R., Uggenti, C., Tata, A.M., Luvisetto, S., Pavone, F., The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes. PLoS One, 10, 2012, e47977.
36. Matak, I., Riederer, P., Lacković, Z., Botulinum toxin's axonal transport from periphery to the spinal cord. Neurochem. Int. 61 (2012), 236–239.
37. Mika, J., Osikowicz, M., Makuch, W., Przewlocka, B., Minocycline and pentoxyfilline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. Eur. J. Pharmacol. 560 (2007), 142–149.
38. Mika, J., Korostynski, M., Kaminska, D., Wawrzczak-Bargiela, A., Osikowicz, M., Makuch, W., Przewlocki, R., Przewlocka, B., Interleukin-1 alpha has antiallodynic and antihyperalgesic activities in a rat neuropathic pain model. Pain 138 (2008), 587–597.
39. Mika, J., Osikowicz, M., Rojewska, E., Korostynski, M., Wawrzczak-Bargiela, A., Przewlocki, R., Przewlocka, B., Differential activation of spinal microglial and astroglial cells in a mouse model of peripheral neuropathic pain. Eur. J. Pharmacol. 623 (2009), 65–72.
40. Mika, J., Rojewska, E., Makuch, W., Przewlocka, B., Minocycline reduces the injury-induced expression of prodynorphin and pronociceptin in the dorsal root ganglion in a rat model of neuropathic pain. Neuroscience 165 (2010), 1420–1428.
41. Mika, J., Rojewska, E., Makuch, W., Korostynski, M., Luvisetto, S., Marinelli, S., Pavone, F., Przewlocka, B., The effect of botulinum neurotoxin A on sciatic nerve injury-induced neuroimmunological changes in rat dorsal root ganglia and spinal cord. Neuroscience 175 (2011), 358–366.
42. Mika, J., Zychowska, M., Popiolek-Barczyk, K., Rojewska, E., Przewlocka, B., Importance of glial activation in neuropathic pain. Eur. J. Pharmacol. 716 (2013), 106–119.
43. Miyoshi, K., Obata, K., Kondo, T., Okamura, H., Noguchi, K., Interleukin-18-mediated microglia/astrocyte interaction in the spinal cord enhances neuropathic pain processing after nerve injury. J. Neurosci. 28 (2008), 12775–12787.
44. Moore, K.W., O'Garra, A., de Waal Malefyt, R., Vieira, P., Mosmann, T.R., Interleukin-10. Annu. Rev. Immunol. 11 (1993), 165–190.
45. Montecucco, C., Molgo, J., Botulinal neurotoxins: revival of an old killer. Curr. Opin. Pharmacol. 5 (2005), 274–279.
46. Narita, M., Yoshida, T., Nakajima, M., Direct evidence for spinal cord microglia in the development of a neuropathic pain-like state in mice. J. Neurochem. 97 (2006), 1337–1348.
47. Nessler, S., Dodel, R., Bittner, A., Reuss, S., Du, Y., Hemmer, B., Sommer, N., Effect of minocycline in experimental autoimmune encephalomyelitis. Ann. Neurol. 52 (2002), 689–690 author reply 690.
48. Novick, D., Kim, S.H., Fantuzzi, G., Reznikov, L.L., Dinarello, C.A., Rubinstein, M., Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 10 (1999), 127–136.
49. Oprée, A., Kress, M., Involvement of the proinflammatory cytokines tumor necrosis factor-alpha, IL-1beta, and IL-6 but not IL-8 in the development of heat hyperalgesia: effects on heat-evoked calcitonin gene-related peptide release from rat skin. J. Neurosci. 20 (2000), 6289–6293.
50. Obreja, O., Schmelz, M., Poole, S., Kress, M., Interleukin-6 in combination with its soluble IL-6 receptor sensitises rat skin nociceptors to heat, in vivo. Pain 96 (2002), 57–62.
51. Oka, T., Aou, S., Hori, T., Intracerebroventricular injection of interleukin-1 beta induces hyperalgesia in rats. Brain Res. 624 (1993), 61–68.
52. Pantano, S., Montecucco, C., The blockade of the neurotransmitter release apparatus by botulinum neurotoxins. Cell Mol. Life Sci. 71 (2014), 793–811.
53. Papagiannopoulou, D., Vardouli, L., Dimitriadis, F., Apostolidis, A., Retrograde transport of radiolabelled botulinum neurotoxin type A to the CNS after intradetrusor injection in rats. BJU Int. 117:4 (2016), 697–704.
54. Park, H.J., Lee, Y., Lee, J., Park, C., Moon, D.E., The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain. Can. J. Anaesth. 53 (2006), 470–477.
55. Pavone, F., Luvisetto, S., Botulinum neurotoxin for pain management: insights from animal models. Toxins 2 (2010), 2890–2913.
56. Pilat, D., Rojewska, E., Jurga, A.M., Piotrowska, A., Makuch, W., Przewlocka, B., Mika, J., IL-1 receptor antagonist improves morphine and buprenorphine efficacy in a rat neuropathic pain model. Eur. J. Pharm. 764 (2015), 240–248.
57. Pilat, D., Piotrowska, A., Rojewska, E., Jurga, A., Ślusarczyk, J., Makuch, W., Basta-Kaim, A., Przewlocka, B., Mika, J., Blockade of IL-18 signaling diminished neuropathic pain and enhanced the efficacy of morphine and buprenorphine. Mol. Cell. Neurosci. 71 (2016), 114–124.
58. Raghavendra, V., Tanga, F., DeLeo, J.A., Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J. Pharmacol. Exp. Ther. 306 (2003), 624–630.
59. Randall, L.O., Selitto, J.J., A method for measurement of analgesic activity on inflamed tissues. Arch. Int. Pharm. Thér. 111 (1957), 409–419.
60. Ranoux, D., Attal, N., Morain, F., Bouhassira, D., Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann. Neurol. 64 (2008), 274–283.
61. Restani, L., Giribaldi, F., Manich, M., Bercsenyi, K., Menendez, G., Rossetto, O., Caleo, M., Schiavo, G., Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons. PLoS Pathog., 8, 2012, e1003087.
62. Rogóż, Z., Potentiation of the antidepressant-like effect of desipramine or reboxetine by metyrapone in the forced swimming test in rats. Pharm. Rep. 61 (2009), 1173–1178.
63. Rojewska, E., Popiolek-Barczyk, K., Jurga, A.M., Makuch, W., Przewlocka, B., Mika, J., Involvement of pro- and antinociceptive factors in minocycline analgesia in rat neuropathic pain model. J. Neuroimmunol. 277 (2014), 57–66.
64. Sapadin, A.N., Fleischmajer, R., Tetracyclines: nonantibiotic properties and their clinical implications. J. Am. Acad. Dermatol. 54 (2006), 258–265 (Review).
65. Schiavo, G., Matteoli, M., Montecucco, C., Neurotoxins affecting neuroexocytosis. Physiol. Rev. 80 (2000), 717–766.
66. Schiavo, G., Montecucco, C., Tetanus and botulism neurotoxins: isolation and assay. Methods Enzym. 248 (1995), 643–652.
67. Snyder, D.A., Kelly, M.L., Woodbury, D.J., SNARE complex regulation by phosphorylation. Cell Biochem. Biophys. 45 (2006), 111–123.
68. Sorkin, L., Svensson, C.I., Jones-Cordero, T.L., Hefferan, M.P., Campana, W.M., Spinal p38 mitogen-activated protein kinase mediates allodynia induced by first-degree burn in the rat. J. Neurosci. Res. 87 (2009), 948–955.
69. Sweitzer, S., Martin, D., DeLeo, J.A., Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain. Neuroscience 103 (2001), 529–539.
70. Thomas, M., Le, W.D., Minocycline: neuroprotective mechanisms in Parkinson's disease. Curr. Pharm. Des. 10 (2004), 679–686 (Review).
71. Verri, W.A. Jr., Cunha, T.M., Parada, C.A., Poole, S., Liew, F.Y., Ferreira, S.H., Cunha, F.Q., Antigen-induced inflammatory mechanical hypernociception in mice is mediated by IL-18. Brain Behav. Immun. 21 (2007), 535–543.
72. Wiegand, H., Erdmann, G., Wellhoner, H.H., 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch. Pharmacol. 292 (1976), 161–165.
73. Yuan, R.Y., Sheu, J.J., Yu, J.M., Chen, W.T., Tseng, I.J., Chang, H.H., Hu, C.J., Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 72 (2009), 1473–1478.
74. Zemke, D., Majid, A., The potential of minocycline for neuroprotection in human neurologic disease. Clin. Neuropharmacol. 27 (2004), 293–298 (Review).
75. Zimmermann, M., Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16 (1983), 109–110.